KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Debt: 2011-2024

Historic Total Debt for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Dec 2024 value amounting to $47.3 million.

  • Supernus Pharmaceuticals' Total Debt fell 75.88% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.2 million, marking a year-over-year decrease of 31.51%. This contributed to the annual value of $47.3 million for FY2024, which is 9.08% down from last year.
  • As of FY2024, Supernus Pharmaceuticals' Total Debt stood at $47.3 million, which was down 9.08% from $52.1 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Total Debt registered a high of $424.1 million during FY2021, and its lowest value of $21.1 million during FY2022.
  • In the last 3 years, Supernus Pharmaceuticals' Total Debt had a median value of $47.3 million in 2024 and averaged $40.2 million.
  • Its Total Debt has fluctuated over the past 5 years, first spiked by 1,272.47% in 2021, then plummeted by 95.02% in 2022.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Total Debt stood at $30.9 million in 2020, then surged by 1,272.47% to $424.1 million in 2021, then plummeted by 95.02% to $21.1 million in 2022, then soared by 146.54% to $52.1 million in 2023, then dropped by 9.08% to $47.3 million in 2024.